Neurotez

Neurotez has a plan to cure Alzheimer’s. This disease affects more than 5 million Americans and 40 million people worldwide.

The company is developing a drug that focuses on restoring a hormone in the brain called Leptin. Scientists believe this hormone plays a significant role in learning and memory. And Leptin levels in patients with Alzheimer’s decrease rapidly.

Neurotez is led by an experienced team with a dozen Ph.Ds in medicine and science and 50 years in the pharmaceutical industry. The company has received more than $4 million in funding from the National Institutes of Health and the New Jersey Commission of Science and Technology.

Neurotez aims to enter Phase 1 and 2 testing in the next 12 to 18 months.

Team Background

George Perry - Chief Science Officer

Jukka Karjalainen - COO

Jane Johnston - VP Operations

Michael Hoy - VP Regulatory Affairs

Co-Investors

National Institutes of Health

An agency of the U.S. Department of Health and Human Services, the NIH is the primary agency of the United States government responsible for biomedical and health-related research. The NIH both conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.

New Jersey Commission of Science and Technology

A state-run organization dedicated to promoting academic and technological research in New Jersey.